Suppr超能文献

测定血液透析液中的草酸盐含量以评估原发性高草酸尿症的透析充分性。

Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria.

作者信息

Tang Xiaojing, Voskoboev Nikolay V, Wannarka Stacie L, Olson Julie B, Milliner Dawn S, Lieske John C

机构信息

Nephrology and Hypertension Research, Mayo Clinic, Rochester, Minn., USA.

出版信息

Am J Nephrol. 2014;39(5):376-82. doi: 10.1159/000360624. Epub 2014 Apr 26.

Abstract

BACKGROUND

Patients with primary hyperoxaluria (PH) overproduce oxalate which is eliminated via the kidneys. If end-stage kidney disease develops they are at high risk for systemic oxalosis, unless adequate oxalate is removed during hemodialysis (HD) to equal or exceed ongoing oxalate production. The purpose of this study was to validate a method to measure oxalate removal in this unique group of dialysis patients.

METHODS

Fourteen stable patients with a confirmed diagnosis of PH on HD were included in the study. Oxalate was measured serially in hemodialysate and plasma samples in order to calculate rates of oxalate removal. HD regimens were adjusted according to a given patient's historical oxalate production, amount of oxalate removal at dialysis, residual renal clearance of oxalate, and plasma oxalate levels.

RESULTS

After a typical session of HD, plasma oxalate was reduced by 78.4 ± 7.7%. Eight patients performed HD 6 times/week, 2 patients 5 times/week, and 3 patients 3 times/week. Combined oxalate removal by HD and the kidneys was sufficient to match or exceed endogenous oxalate production. After a median period of 9 months, pre-dialysis plasma oxalate was significantly lower than initially (75.1 ± 33.4 vs. 54.8 ± 46.6 mmol/l, p = 0.02).

CONCLUSION

This methodology can be used to individualize the dialysis prescription of PH patients to prevent oxalosis during the time they are maintained on HD and to reduce risk of oxalate injury to a transplanted kidney.

摘要

背景

原发性高草酸尿症(PH)患者草酸盐产生过多,通过肾脏排出。如果发展为终末期肾病,他们发生全身性草酸中毒的风险很高,除非在血液透析(HD)期间清除足够的草酸盐以等于或超过持续的草酸盐产生量。本研究的目的是验证一种测量这一独特透析患者群体草酸盐清除率的方法。

方法

14例确诊为HD的PH稳定患者纳入研究。连续测量血液透析液和血浆样本中的草酸盐,以计算草酸盐清除率。根据给定患者既往的草酸盐产生量、透析时的草酸盐清除量、草酸盐的残余肾清除率和血浆草酸盐水平调整HD方案。

结果

经过一次典型的HD治疗后,血浆草酸盐降低了78.4±7.7%。8例患者每周进行6次HD,2例患者每周进行5次,3例患者每周进行3次。HD和肾脏联合清除草酸盐足以匹配或超过内源性草酸盐产生量。经过9个月的中位期后,透析前血浆草酸盐显著低于初始水平(75.1±33.4 vs.54.8±46.6 mmol/l,p = 0.02)。

结论

该方法可用于个体化PH患者的透析处方,以防止在HD维持期间发生草酸中毒,并降低移植肾草酸盐损伤的风险。

相似文献

1
Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria.
Am J Nephrol. 2014;39(5):376-82. doi: 10.1159/000360624. Epub 2014 Apr 26.
2
Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1.
Kidney Int. 2006 Nov;70(9):1642-8. doi: 10.1038/sj.ki.5001806. Epub 2006 Sep 6.
3
Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure.
Kidney Int. 1999 Jul;56(1):268-74. doi: 10.1046/j.1523-1755.1999.00546.x.
4
Nocturnal home hemodialysis for a patient with type 1 hyperoxaluria.
Am J Kidney Dis. 2013 Dec;62(6):1155-9. doi: 10.1053/j.ajkd.2013.05.013. Epub 2013 Jul 4.
5
Oxalate removal by daily dialysis in a patient with primary hyperoxaluria type 1.
Nephrol Dial Transplant. 2001 Dec;16(12):2407-11. doi: 10.1093/ndt/16.12.2407.
7
Plasma oxalate following kidney transplantation in patients without primary hyperoxaluria.
Nephrol Dial Transplant. 2010 Jul;25(7):2341-5. doi: 10.1093/ndt/gfq065. Epub 2010 Feb 17.
9
Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.
Nephrol Dial Transplant. 2011 Nov;26(11):3609-15. doi: 10.1093/ndt/gfr107. Epub 2011 Apr 2.
10
Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure.
Pediatr Nephrol. 1996 Aug;10(4):488-92. doi: 10.1007/s004670050145.

引用本文的文献

1
A Targeted Release Capsule of Lanthanum Carbonate: a New Efficient Cheap Treatment for Primary Hyperoxalurias.
Kidney Int Rep. 2024 Nov 21;10(2):503-515. doi: 10.1016/j.ekir.2024.11.020. eCollection 2025 Feb.
2
Diagnosis and management of primary hyperoxalurias: best practices.
Pediatr Nephrol. 2024 Nov;39(11):3143-3155. doi: 10.1007/s00467-024-06328-2. Epub 2024 May 16.
4
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope.
Nat Rev Nephrol. 2023 Mar;19(3):194-211. doi: 10.1038/s41581-022-00661-1. Epub 2023 Jan 5.
5
Treatment of primary hyperoxaluria type 1.
Clin Kidney J. 2022 May 17;15(Suppl 1):i9-i13. doi: 10.1093/ckj/sfab232. eCollection 2022 May.
7
Natural History of Clinical, Laboratory, and Echocardiographic Parameters of a Primary Hyperoxaluria Cohort on Long Term Hemodialysis.
Front Med (Lausanne). 2021 Apr 9;8:592357. doi: 10.3389/fmed.2021.592357. eCollection 2021.
8
Accelerated Oxalosis Contributing to Delayed Graft Function after Renal Transplantation.
Case Rep Transplant. 2019 Mar 25;2019:8942062. doi: 10.1155/2019/8942062. eCollection 2019.
9
Oxalosis Associated With High-Dose Vitamin C Ingestion in a Peritoneal Dialysis Patient.
Am J Kidney Dis. 2019 Sep;74(3):417-420. doi: 10.1053/j.ajkd.2019.01.022. Epub 2019 Mar 22.
10
Primary Hyperoxaluria Type 1 with Thrombophilia in Pregnancy: A Case Report.
Case Rep Nephrol Dial. 2018 Oct 4;8(3):223-229. doi: 10.1159/000493091. eCollection 2018 Sep-Dec.

本文引用的文献

1
Hereditary causes of kidney stones and chronic kidney disease.
Pediatr Nephrol. 2013 Oct;28(10):1923-42. doi: 10.1007/s00467-012-2329-z. Epub 2013 Jan 20.
2
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment.
Nephrol Dial Transplant. 2012 May;27(5):1729-36. doi: 10.1093/ndt/gfs078.
3
Transplantation outcomes in primary hyperoxaluria.
Am J Transplant. 2010 Nov;10(11):2493-501. doi: 10.1111/j.1600-6143.2010.03271.x. Epub 2010 Sep 17.
5
Frequent hemodialysis with NxStage system in pediatric patients receiving maintenance hemodialysis.
Pediatr Nephrol. 2008 Jan;23(1):129-35. doi: 10.1007/s00467-007-0649-1. Epub 2007 Nov 8.
6
A comparison of center-based vs. home-based daily hemodialysis for patients with end-stage renal disease.
Hemodial Int. 2007 Oct;11(4):468-77. doi: 10.1111/j.1542-4758.2007.00229.x.
7
Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1.
Kidney Int. 2006 Nov;70(9):1642-8. doi: 10.1038/sj.ki.5001806. Epub 2006 Sep 6.
8
Sensitive spectrophotometric assay for plasma oxalate.
Clin Chem. 2005 Dec;51(12):2377-80. doi: 10.1373/clinchem.2005.054353.
9
Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele.
Kidney Int. 2005 May;67(5):1704-9. doi: 10.1111/j.1523-1755.2005.00267.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验